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Abstract
To systematically review the literature for dementia prediction models for use in the general population and externally
validate their performance in a head-to-head comparison. We selected four prediction models for validation: CAIDE,
BDSI, ANU-ADRI and DRS. From the Rotterdam Study, 6667 non-demented individuals aged 55 years and older were
assessed between 1997 and 2001. Subsequently, participants were followed for dementia until 1 January, 2015. For each
individual, we computed the risk of dementia using the reported scores from each prediction model. We used the C-statistic
and calibration plots to assess the performance of each model to predict 10-year risk of all-cause dementia. For com-
parisons, we also evaluated discriminative accuracy using only the age component of these risk scores for each model
separately. During 75,581 person-years of follow-up, 867 participants developed dementia. C-statistics for 10-year
dementia risk prediction were 0.55 (95% CI 0.53–0.58) for CAIDE, 0.78 (0.76–0.81) for BDSI, 0.75 (0.74–0.77) for ANU-
ADRI, and 0.81 (0.78–0.83) for DRS. Calibration plots showed that predicted risks were too extreme with underestimation
at low risk and overestimation at high risk. Importantly, in all models age alone already showed nearly identical dis-
criminative accuracy as the full model (C-statistics: 0.55 (0.53–0.58) for CAIDE, 0.81 (0.78–0.83) for BDSI, 0.77
(0.75–0.79) for ANU-ADRI, and 0.81 (0.78–0.83) for DRS). In this study, we found high variability in discriminative
ability for predicting dementia in an elderly, community-dwelling population. All models showed similar discriminative
ability when compared to prediction based on age alone. These findings highlight the urgent need for updated or new
models to predict dementia risk in the general population.
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Introduction
Dementia poses an ever-increasing burden on societies
worldwide, indicating the urgent need to develop effective
therapeutic solutions [1]. Over the last two decades, many
pharmacological trials have been conducted to halt or
reverse the underlying neurodegenerative process, but have
failed to develop disease-modifying therapeutics [2].
Besides the development of treatment strategies in
advanced disease stages, there is increasing focus on
developing preventive intervention approaches in early
disease or asymptomatic states to delay or even prevent the
onset of dementia [3, 4]. This shift has been further fueled
by recent findings that up to a third of all dementia cases
could be prevented if currently known modifiable risk
factors were eliminated at a population level [5, 6]. How-
ever, a few randomized controlled trials that assessed the
efficacy of multi-domain interventions in asymptomatic
individuals to prevent cognitive decline or dementia have
been inconsistent [7–10]. Moreover, targeting asymp-
tomatic individuals in an unselected population requires
expensive trials with large sample sizes and long follow-up
duration. In order to make future trials more successful,
preventive measures may therefore need to target individ-
uals at high-risk of developing dementia. This requires a
valid and reliable method for the identification of high-risk
individuals.
Prediction models can be used to discriminate between
high- and low-risk individuals, which in turn could result in
more tailored selection of individuals for future clinical
trials and preventive interventions [11–13]. For dementia,
numerous prediction models have been developed over the
past years, but for many external validation is lacking
[3, 13–15]. A recent systematic review highlighted four
models that were most promising for transportability out-
side the data they were developed on [14]. In order to
facilitate practical implementation of any of these predic-
tion models, a direct head-to-head comparison of these
prediction models would provide essential information
about how the performances compare with each other
[15–17]. Therefore, we externally validated four prediction
models for dementia in a community-dwelling population.
Methods
Ethics statement
The Rotterdam Study has been approved by the Medical
Ethics Committee of the Erasmus MC and by the Ministry
of Health, Welfare and Sport of the Netherlands, imple-
menting the Wet Bevolkingsonderzoek: ERGO (Population
Studies Act: Rotterdam Study). All participants provided
written informed consent to participate in the study and to
obtain information from their treating physicians.
Selection of prediction models for external
validation
We used a recently published systematic review to identify
dementia prediction models [14]. This review identified
four models as most promising for practical implementa-
tion as preliminary validation was already undertaken on
them [18–21]. For this study, we excluded one model as
this was developed specifically for individuals with type 2
diabetes [19]. Given that the literature search in this sys-
tematic review was last done in March, 2014, we updated
the search [14]. The search included articles published
between March 17, 2014 until March 31, 2017 in electronic
databases (PubMed, Embase, Scopus and, Web of Sci-
ence). We included articles examining the risk of dementia
in non-demented individuals in the general population and
constructing a prediction model in which validation was
attempted. Combinations of the following terms were used:
‘‘dementia’’, ‘‘risk’’, ‘‘score’’, ‘‘assessment’’, ‘‘prediction’’,
‘‘model’’, and ‘‘validation’’. Additionally, we searched the
reference lists of relevant publications to complement the
electronic search strategy. One additional prediction model
was identified according to the same criteria used in the
systematic review and therefore included in our analyses
[22]. Therefore, in total, we included four prediction
models in a head-to-head comparison.
Prediction models included for analysis
The specific models and the studies in which these were
developed are briefly described below, with additional data
on the original study and model characteristics described in
Appendix A. Definitions and distributions of included
variables from the corresponding studies are presented in
Appendix B, Supplementary Tables 1 and 2.
Cardiovascular Risk Factors, Aging,
and Dementia (CAIDE)
The CAIDE risk score was originally developed in a
midlife population (N = 1409) to predict dementia risk
during 20 years of follow-up [18]. The model included age
(\ 47 years: 0 points, 47–53 years: 3 points and
[ 53 years: 4 points), sex (men: 1 point), education
(C 10 years: 0 points, 7–9 years: 2 points, 0–6 years: 3
points), hypertension ([ 140 mmHg: 2 points), body mass
index ([ 30 kg/m2: 2 points), cholesterol ([ 6.5 mmol/L:
2 points), and physical activity (inactivity: 1 point).
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Brief Dementia Screening Indicator (BDSI)
The BDSI was developed and validated using four popu-
lation-based cohort studies (N = 20,219) to identify indi-
viduals aged 65–79 years at increased risk of dementia
who could be targeted for cognitive screening in a primary
care setting during 6 years of follow-up [20]. The model
included age (1 point/year), education (\ 12 years: 9
points), body mass index (\ 18.5 kg/m2: 8 points), pres-
ence of diabetes (3 points), history of stroke (6 points),
assistance needed with finances or medications (10 points),
and depressive symptoms (6 points).
Australian National University Alzheimer’s
Disease Risk Index (ANU-ADRI)
The ANU-ADRI was developed to assess an individual’s
risk for late-life Alzheimer’s disease based on self-reported
risk factors [23]. The model included 15 risk factors: age
and sex (scores stratified on sex, ranging from 0 points for
men aged\ 65 years to 41 points for women aged C 90
years), educational level (8–11 years: 3 points,[ 11 years:
6 points), presence of diabetes (3 points), presence of
traumatic brain injury (4 points), presence of depressive
symptoms (2 points), high cholesterol (3 points), presence
of cognitively stimulating activities (low 0, moderate: - 6
and high: - 7 points), strength of social network (high: 0,
medium–high: 1 point, medium–low: 4 points and low: 6
points), smoking (former: 1 point, current: 4 points),
alcohol consumption (abstainers: 0 points, and light to
moderate - 3 points), level of physical activity (low: 0
points, medium: - 2 points, high: - 3 points), body mass
index (normal: 0 points, overweight: 2 points, and obese 5
points), fish intake (\ 0.25 serves/week: 0 points, 0.26–2.0:
- 3 points, 2.1–4.0: - 4 points, C 4.1: - 5 points), and
pesticide exposure (2 points). The model was tested and
validated in three population-based cohort studies
(N = 5840) [21].
Dementia Risk Score (DRS)
This model was not identified in the original systematic
review, but included for analysis based on our updated
literature search. Using The Health Improvement Network
(THIN), a database that derived data from routine clinical
practice, the DRS was developed and validated to predict a
5-year risk of dementia [22]. The study population was
dichotomized based on baseline age for analysis
(60–79 years (N = 800,013) and 80–95 years
(N = 130,382)). Included predictors per age group are
shown in Supplementary Table 1. The risk (P) for an
individual aged 60–79 years can be calculated using the
following formula: 0.20921 9 (age - 65.608) ?
- 0.00339 9 (age - 65.608) 9 (age - 65.608) ?
- 0.0616 9 (body mass index - 27.501) ? 0.002508 9
(body mass index - 27.501) 9 (body mass index
- 27.501) ? 0.12854 9 (female) ? 0.13199 9 (hyper-
tension) ? 0.04477 9 (current calender year - 2003.719)
? 0.013371 9 (depreviation quintile 2) ? 0.117904 9
(depreviation quintile 3) ? 0.201776 9 (depreviation
quintile 4) ? 0.225529 9 (depreviation quintile 5) ?
- 0.06792 9 (former smoker) ? - 0.08657 9 (current
smoker) ? 0.443535 9 (heavy drinking) ? 0.833612 9
(current depression and/or use of antidepressants) ?
0.252833 9 (current aspirin use) ? 0.577207 9 (history
of stroke or TIA) ? 0.220728 9 (history of atrial fibrilla-
tion) ? 0.286701 9 (history of diabetes). With a baseline
hazard of 0.9969. The predicted 5-year risk as a percentage
is then calculated as follows: 100 9 [1 - Sexp(P)].
Study population of the external validation
cohort
Participants were recruited within the Rotterdam Study, a
prospective population-based cohort study. In 1990, all
residents aged 55 and older residing in Ommoord, a district
of Rotterdam, the Netherlands, were invited. Of the 10,215
invited inhabitants, 7983 (78%) agreed to participate in the
baseline examination. In 2000, the cohort was extended: all
residents aged 55 and older of the same district were
invited, except for the participants that were already in the
original cohort. Of the 4472 invitees, 3011 (67%) agreed to
participate. Follow-up examinations take place every
3–4 years [5, 24].
Analyses of this study are based on data obtained from
the third follow-up round of the original wave undertaken
1997–1999 (N = 4797) and the first round of the extended
wave undertaken 2000–2001 (N = 3011). While these
study waves had different initiation dates, they were similar
in design and participants came from the same source
population, i.e. Ommoord, a suburb of Rotterdam, the
Netherlands. After excluding participants who did not
complete the interview and research center visit in these
rounds (N = 873), had dementia or insufficient screening
for dementia at baseline (N = 99), did not provide
informed consent to access medical records and hospital
discharge letters (N = 149), or if there was no follow-up
due to logistic reasons (N = 20), 6667 participants were
included for analysis in this study, of whom 3983 partici-
pants came from the original wave (83.0% of surviving
participants), and 2684 participants (89.1%) from the
extended wave. Results have been reported to conform
with the TRIPOD statement [25].
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Assessment of dementia
Participants were screened for dementia at baseline and
subsequent center visits with the Mini-Mental State
Examination and the Geriatric Mental Schedule organic
level [5]. Those with a Mini-Mental State Examination
score\ 26 or Geriatric Mental Schedule score[ 0
underwent further investigation and informant interview,
including the Cambridge Examination for Mental Disor-
ders of the Elderly. All participants also underwent routine
cognitive assessment. In addition, the entire cohort was
continuously under surveillance for dementia through
electronic linkage of the study database with medical
records from general practitioners and the regional institute
for outpatient mental health care. The information from in-
person screening was supplemented by data from the
electronic linkage of the study database with medical
records from all general practitioners and the regional
institute for outpatient mental health care. In the Dutch
healthcare system, the entire population is entitled to pri-
mary care that is covered by their (obligatory) health
insurance. The general practitioner functions as a ‘gate-
keeper’ for referral to secondary and tertiary care provi-
ders, who are required by law to report back to the referring
general practitioner about test results and clinical diag-
noses. With this linkage, the entire cohort is thus contin-
uously monitored for detection of interval cases of
dementia or cognitive disturbances between center visits.
Study physicians biannually evaluate all records, and
combine information from medical records with in-person
screening to draw up individual case reports. In these
reports, the physicians covered all gathered relevant
information to establish the presence, probability and
subtype of dementia. Available information on cognitive
testing and clinical neuroimaging was only used if required
for diagnosis of dementia subtype. Available information
on cognitive testing and clinical neuroimaging was used
when required for diagnosis of dementia subtype. A con-
sensus panel led by a consultant neurologist established the
final diagnosis according to standard criteria for dementia
(DSM-III-R) and Alzheimer’s disease (NINCDS–
ADRDA). Follow-up for incident dementia was near-
complete (97.5% of potential person-years) until 1 January,
2015 [26]. Within this period, participants were censored at
date of dementia diagnosis, death, loss to follow-up, or 1st
January 2015, whichever came first.
Assessment of predictors
The predictors used in this validation study are based on
the component variables included in the different published
risk prediction models and are described in detail in
Supplementary Appendix B. We had to make a few
adjustments to the included variables due to different
measurement methods as compared to the original models.
For the CAIDE model, we measured physical activity using
the Zutphen physical activity questionnaire [27]. We did
not have data available on the frequency of physical
activities per week, therefore we defined being physically
active based on a minimum of C 40 min of exercise per
week with a metabolic equivalent of task (MET) intensity
of C 4. For the ANU-ADRI model, we reduced the social
engagement predictor from five to three domains in our
model (based on marital status, living status, and loneli-
ness). We were unable to include pesticide exposure and
cognitive activity in this model, as these are not system-
atically measured within the Rotterdam Study. In the DRS
model, the Townsend deprivation index was used to indi-
cate neighborhood deprivation. This index is uniquely used
in the United Kingdom. We therefore constructed a similar
composite score based on living status, marital status, and
loneliness to emulate this index in our sample. Use of such
composite scores of socio-demographic domains to sum-
marize neighborhood deprivation have been used and val-
idated previously [28]. In addition, the DRS included
anxiety disorders, but we did not have questionnaires
available to assess anxiety symptoms. Therefore, we
defined anxiety symptoms as present if participants used
anxiolytic drugs (Anatomical Therapeutic Chemical Clas-
sification codes N05B).
Statistical analysis
We evaluated two measures of model performance: dis-
crimination and calibration. Discrimination refers to the
capability of a risk score to correctly differentiate between
two participants, one who will develop the outcome during
follow-up and one who will not [29]. We used C-statistics
to assess the discriminative ability of the models. Cali-
bration is the agreement between the risks predicted by the
model and the observed frequencies of the outcomes under
study, which we evaluated using calibration plots [29].
We present three sequential analyses to compare the
discriminative performance of the models in the validation
cohort. First, we evaluated the performance of the models
in the age ranges for which they were originally designed.
We computed the risk scores for each participant exactly as
published in the original publication for each prediction
model. If this was not provided, we used the linear pre-
dictor, which represents the sum of all regression
coefficients.
Second, we validated all models in the entire study
population to directly compare the performance of all
models across the entire age range. We needed to perform a
few adjustments to the original risk scores to be able to
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make this direct comparison, because some of the included
prediction models were designed for specific age ranges,
which were narrower than our study population. The BDSI
was originally developed for a population aged
65–79 years old, ranking individuals with 1 point extra per
year increase in age. We therefore extrapolated the corre-
sponding BDSI score for participants outside this range in
this validation study using the same point increase in age.
The DRS used two separate risk equations for different age
strata. As these equations did not capture the entire age
range within this validation study, we used the risk equa-
tion designed for a 60–79-year-old population for all par-
ticipants below 79 years of age and the risk equation for a
80–95-year-old population for participants above 80 years
of age for this analysis. Third, to quantify the added pre-
dictive value of other predictors in the models, we evalu-
ated the predictive accuracy of the models based on age
alone, the strongest risk factor for dementia, and based on
all risk factors with the exception of age.
Predicted time horizons differed across the original
studies, ranging from 5 to 20 years. For all analyses, we
focused on 10-year dementia risk in all four models to
facilitate a fair comparison. We additionally studied the
performance of the models with follow-up of 2, 5, and
15 years. We truncated the follow-up for participants with
longer follow-up time than these horizons.
To assess calibration, we constructed 10-year risk cali-
bration plots and evaluated the intercept and calibration
slope of these plots to test the goodness-of-fit of the models
[29]. Furthermore, we recalibrated original logistic
regression models by updating the intercept. For Cox
models, we updated the baseline survival function and used
the mean predictor values of the validation study to account
for possible differences in disease incidence and risk factor
distribution [30, 31].
Sensitivity analyses
In sensitivity analyses, (1) we assessed the predictive
accuracy for Alzheimer’s disease specifically, (2) we
repeated the analyses of a 10- and 15-year time horizon
with exclusion of participants with less than 4 years of
dementia-free follow-up to reduce the possibility of reverse
causality (i.e. prodromal dementia leading to a higher risk
score), and (3) we stratified on age (80 years) at baseline,
given the steep increase in incidence of dementia beyond
this age in order to further investigate the performance of
the models in different age strata.
Missing data on covariates were imputed using 5-fold
multiple imputation, based on all predictors, outcome sta-
tus, and follow-up time. All analyses were done using IBM
SPSS (version 21.0) and R, CRAN version 3.3.2 (rms [32],
val.prob.ci.2 packages [33]).
Results
In Table 1 the baseline characteristics of the study sample
are presented. Missing data on the included predictors for
this validation study was relatively low (\ 8.7% missing),
except for head trauma (40.9%) and fish servings per week
(48.1%) as these were only measured in one of the two
included study waves. The mean age was 69.1 years
(standard deviation 8.2) and 57.0% were women. 2466
(37%) of all participants were middle-aged (\ 65 years
old), of whom 1377 (55.8%) were women. The median
follow-up time for the full sample was 13.2 years (in-
terquartile range 10.1–16.3), with a median follow-up of
12.5 years (8.4–16.6) for the original wave and 13.6 years
(11.9–15.3) for the extended wave, respectively. During a
total follow-up of 75,581 person-years, 867 participants
developed dementia, 696 of whom developed Alzheimer’s
disease. This corresponds to a crude incidence rate for all-
cause dementia of 11.5 per 1000 person-years.
Discrimination
As the BDSI and DRS models were designed for a specific
age range, we first evaluated their performance in this age
range using a comparable predicted time horizon. The
models showed slightly attenuated discriminative ability in
this validation study (C-statistic: 0.69 (95% CI 0.64–0.73)
for the BDSI and 0.77 (0.72–0.81) for the DRS) compared
to the original development samples (C-statistics: ranging
from 0.68 to 0.78 for BDSI and 0.84 (0.81–0.87) for the
DRS).
Table 2 shows the discriminative ability for all models
across the entire age range within our validation sample.
The BDSI, ANU-ADRI, and DRS showed the highest
C-statistics at 10-year horizons. These models all contained
the predictors age, history of diabetes, and presence of
depressive symptoms. Using different predicted horizons,
C-statistics ranged from 0.55 for the CAIDE to 0.84 for the
DRS model, both at predicting a 2-year risk of dementia.
Importantly, calculating the C-statistics based on the age
component of the models only, showed nearly identical
discriminative abilities compared with the full models for
all predicted horizons. This applied for the specific age
ranges (Supplementary Table 3) and for the entire age
range within our sample (Table 2). Conversely, excluding
the age component from the risk scores showed very poor
predictive abilities for all models (Table 2). Discriminative
ability based on the age component alone could not be
calculated for the CAIDE model as all participants within
this validation study were in the oldest age group according
to this model. Hence, the C-statistics for this model can be
best compared to the C-statistics of the other models
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Table 1 Baseline characteristics of the validation cohort
All participants
N = 6667
Missing
data (%)
Original study
wave
N = 3983
Missing
data (%)
Extended study
wave
N = 2684
Missing
data (%)
Age, years 69.1 (8.2) 0 72.2 (7.0) 0 64.6 (7.9) 0
Women 3787 (56.8%) 0 2306 (57.9%) 0 1481 (55.2%) 0
Body mass index, kg/m2 27.0 (4.0) 1.5 26.9 (4.0) 1.3 27.3 (4.0) 1.6
Systolic blood pressure, mmHg 143 (21) 0.9 144 (21) 0.4 143 (22) 1.4
Education, years 11.4 (3.6) 1.8 11.0 (3.6) 1.4 12.2 (3.5) 2.3
Alcohol use 5477 (82.2%) 1.0 3247 (81.5%) 0.7 2230 (83.1%) 1.4
Smoking 0.9 0.7 1.3
Never 2059 (30.9%) 1289 (32.4%) 770 (28.7%)
Former 3222 (48.3%) 1952 (49.0%) 1270 (47.3%)
Current 1323 (19.8%) 715 (18.0%) 608 (22.7%)
Total cholesterol, mmol/L 5.80 (0.98) 4.1 5.8 (0.98) 3.9 5.8 (0.98) 4.5
High-density lipoprotein cholesterol,
mmol/L
1.39 (0.39) 5.2 1.39 (0.40) 5.7 1.37 (0.37) 4.5
Total-to-HDL-cholesterol ratio 4.47 (1.32) 5.2 4.47 (1.33) 5.7 4.47 (1.30) 4.5
Leisure time physical activity, MET-
hours (IQR)*
77.0 (48.7–105.2) 4.2 78.2 (48.2–108.2) 0.1 75.1
(48.4–101.8)
8.2
History of type 2 diabetes 717 (10.8%) 7.3 437 (11.0%) 7.3 280 (10.4%) 7.3
History of stroke 244 (3.7%) 1.0 156 (3.9%) 1.0 88 (3.3%) 1.0
History of TIA 194 (2.9%) 3.0 112 (2.8%) 3.0 82 (3.1%) 3.2
History of head trauma with
unconsciousness
442 (6.6%) 40.9 442 (11.1%) 1.1 – –
History of atrial fibrillation 335 (5.0%) 2.8 256 (6.4%) 2.4 79 (2.9%) 3.0
Depressive symptoms 508 (7.6%) 4.2 241 (6.1%) 5.7 267 (9.9%) 2.1
Social engagement 0.4 0.6 0.2
High 19 (0.3%) 0 (0%) 19 (0.7%)
Medium–high 661 (9.9%) 174 (4.4%) 487 (18.1%)
Medium–low 4827 (72.4%) 2928 (73.5%) 1899 (70.8%)
Low 1130 (16.9%) 855 (21.5%) 275 (10.2%)
Fish servings per week 48.1 12.9 –
[ 4.1 15 (0.2%) 15 (0.2%) –
2.1–4.1 88 (1.3%) 88 (1.3%) –
0.26–2.0 1837 (27.6%) 1837 (27.6%) –
B 0.25 1529 (22.9%) 1529 (22.9%) –
Needs help with finances or
medications
1180 (17.7%) 7.1 935 (23.5%) 6.8 245 (9.1%) 8.8
Use of antihypertensive drugs 1551 (23.3%) 4.8 962 (24.2%) 4.8 589 (21.9%) 4.6
Use of anxiolytics 790 (11.8%) 0 543 (13.6%) 0 247 (9.2%) 0
Use of aspirin 1158 (17.4%) 0 780 (19.6%) 0 378 (14.1%) 0
Use of NSAIDs (excluding aspirin) 569 (8.5%) 0 331 (8.3%) 0 238 (8.9%) 0
N number of people at risk, lipid ratio ratio between total and high-density lipoprotein cholesterol, MET metabolic equivalent of task, IQR
interquartile range, TIA transient ischemic attack, NSAIDs non-steroidal anti-inflammatory drugs
Data are shown for non-imputed data. Values are counts (valid percentages) or means (standard deviation)
*Presented as median (interquartile range), because of skewed distribution
Used as a social deprivation index for the dementia risk score
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excluding age. With the exception of CAIDE, discrimina-
tive ability was inversely related to the predicted horizon,
with the highest C-statistics when calculating short-term
dementia risks.
Calibration
The required absolute risk equations needed to construct
calibration plots were only reported for the CAIDE and
DRS models (Supplementary Appendix C). In Fig. 1 the
calibration plots are shown for the original and recalibrated
CAIDE models. The CAIDE model tended to systemati-
cally underestimate the risk of dementia (‘calibration-in-
the-large’). The recalibrated CAIDE with updated intercept
still showed poor calibration (intercept = - 0.73, calibra-
tion slope = 0.21), reflecting the poor discriminative ability
of the model in the validation sample. The DRS model also
tended to underestimate risks (Fig. 2). The recalibrated
DRS model using an updated dementia incidence rate and
mean values based on the Rotterdam Study population,
performed better, but still indicated that predictions were
too extreme, particularly for those at high predicted risk
(Fig. 2).
Sensitivity analyses
All models showed similar discriminative performance
based on the age component of the risk score alone. This
applied for all sensitivity analyses: for predicting Alzhei-
mer’s disease specifically (Supplementary Table 3), in
participants with four or more years of dementia-free fol-
low-up (Supplementary Table 4), and in participants below
and above the age of 80 at baseline (Supplementary
Table 5).
Discussion
In this external validation study, we identified four
dementia prediction models based on a previously pub-
lished systematic review complemented by an updated
literature search and showed that these models have widely
varying accuracy for predicting dementia in an elderly,
community-dwelling population. Importantly, in all models
age was the driving factor for the discriminative ability.
Other risk factors included had marginal contributions
above and beyond age. Our results indicate that established
risk factors for dementia that are currently included in these
models have limited added value in dementia prediction
above and beyond age in the general population. Our
results were consistent in several analyses, even when we
compared the performance of the models based on the age
component alone with the performance of the full models
in the specific age ranges on which those models were
originally derived from.
To our knowledge, there is currently no other head-to-head
comparison of multiple dementia prediction models in the
same study population. Other studies only validated one
prediction model or compared the novel model with one other
prediction model in the same study population [21, 34].
We will briefly consider several differences between the
original studies and this validation study, which may have
influenced the observed performance in this study. The
CAIDE dementia risk score was originally developed for a
Table 2 Discriminative ability
for all-cause dementia
Prediction model C-statistics at various follow-up horizons (95% CI)
2 years
n/N = 63/6667
5 years
n/N = 233/6667
10 years
n/N = 515/6667
15 years
n/N = 847/6667
CAIDE 0.49 (0.42–0.56) 0.54 (0.50–0.58) 0.55 (0.53–0.58) 0.55 (0.53–0.57)
Age only NA NA NA NA
Without age 0.49 (0.42–0.56) 0.54 (0.50–0.58) 0.55 (0.53–0.58) 0.55 (0.53–0.57)
BDSI 0.83 (0.75–0.90) 0.80 (0.76–0.84) 0.78 (0.76–0.81) 0.76 (0.74–0.78)
Age only 0.83 (0.76–0.90) 0.81 (0.78–0.85) 0.81 (0.78–0.83) 0.79 (0.77–0.81)
Without age 0.64 (0.57–0.71) 0.63 (0.59–0.66) 0.60 (0.58–0.63) 0.59 (0.57–0.61)
ANU-ADRI 0.81 (0.77–0.86) 0.78 (0.76–0.81) 0.75 (0.74–0.77) 0.70 (0.69–0.72)
Age only 0.83 (0.79–0.87) 0.80 (0.77–0.82) 0.77 (0.75–0.79) 0.72 (0.71–0.74)
Without age 0.56 (0.49–0.64) 0.51 (0.47–0.55) 0.52 (0.49–0.54) 0.51 (0.49–0.53)
DRS 0.84 (0.77–0.92) 0.82 (0.78–0.86) 0.81 (0.78–0.83) 0.79 (0.77–0.81)
Age only 0.83 (0.76–0.90) 0.81 (0.78–0.85) 0.81 (0.78–0.83) 0.79 (0.77–0.81)
Without age 0.63 (0.56–0.70) 0.58 (0.54–0.62) 0.57 (0.55–0.60) 0.55 (0.53–0.57)
CI confidence interval, n number of cases, N number of people at risk, CAIDE cardiovascular risk factors,
aging, and dementia study, NA not applicable, BDSI brief dementia screening indicator, ANU-ADRI
Australian National University Alzheimer’s Disease Risk Index and, DRS dementia risk score
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midlife population and showed poor transportability to our
elderly population. The poor performance in this study is in
line with a previous study which assessed the performance
of the CAIDE risk score in three elderly population-based
cohorts [21]. This reflects the importance of age. Indeed, in
the Rotterdam Study, all participants received the highest
score for age and it was therefore not possible to dis-
criminate participants based on the age component of the
Fig. 1 Calibration plots of the original (left) and recalibrated (right)
Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) model to
predict risk of dementia. In case of perfect calibration all groups of
predicted probabilities fit close to the red diagonal line, corresponding
to an intercept of 0 and a slope of 1 for the calibration plot. Vertical
lines in grouped observations represent 95% confidence intervals.
(Color figure online)
Fig. 2 Calibration plots of the original (left) and recalibrated (right)
Dementia Risk Score (DRS) model to predict risk of dementia. In case
of perfect calibration all groups of predicted probabilities fit close to
the red diagonal line, corresponding to an intercept of 0 and a slope of
1 for the calibration plot. Vertical lines in grouped observations
represent 95% confidence intervals. (Color figure online)
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risk score alone. In addition, this poor performance may
also be due to specific midlife risk factors for dementia,
such as high body mass index and cholesterol level which
are found to have inverse (i.e. protective rather than
increasing risk) associations with dementia in older age
groups [35, 36]. Given these considerable differences, we
note that the application of the CAIDE model in older
adults is limited. The results of the CAIDE model should
therefore be interpreted with caution, yet we also note that
the CAIDE model is increasingly being used in older
populations to select high-risk individuals for clinical trials
[7] and to conduct stratified analyses in high-risk individ-
uals using this score [9]. Results from this study provide
important insights in these transportability issues and
quantify the predictive ability of this model in these
populations.
The BDSI model was originally developed for a
65–79 year old population to identify individuals who
could be targeted for cognitive screening during 6-years of
follow-up. We extrapolated the age component of the
original model to be able to compare this model with other
models across the entire age range. This may have over-
estimated the importance of age in this adjusted model.
Nevertheless, the full model showed similar discriminative
performance compared with the model based on the age
component alone when we evaluated its performance in the
age range it was originally designed for with use of a
comparable predicted time horizon [20].
The ANU-ADRI model was originally developed to
assess an individual’s risk for late-life Alzheimer’s disease.
Although we compared this model with other models in our
main analysis to predict the risk of all-cause dementia,
similar results were seen for Alzheimer’s disease.
The DRS was developed and validated using data derived
from routine clinical practice. For the original model, two
separate risk equations were developed based on an individ-
ual’s age at baseline (60–79 vs. 80–95 years). In this vali-
dation study, we evaluated the performance of this model
using these two risk equations for our entire study population,
which was broader than the age range for which they were
originally developed. This may have affected our results, but
as with the BDSI, the model based on the age component
alone showed comparable predictive accuracies with the full
model when we restricted our analyses to the specific age
ranges for which the risk equations were designed.
All models included established risk factors for
dementia and most often assigned the highest weight to
age, reflecting age as most important risk factor for the
occurrence of dementia. Beyond age, however, other risk
factors appear not to be as important when used as risk
predictors for dementia in an elderly population. Most risk
factors are not very specific for the occurrence of dementia,
whereas risk factors that are also useful as risk predictors
need to be very strongly associated with the disease to
provide additional predictive value. Indeed, we find that
various factors that have been deemed risk factors for
dementia do not add to the prediction of dementia beyond
age alone. Hence, our current analyses are not in conflict
with these factors being risk factors for dementia, but
additionally show that these risk factors do not provide
additional predictive utility beyond age alone. On the other
hand, age reflects a cumulative risk index of exposure to
various risk factors over time. Chronological age therefore
probably yields a summary of predictive information
derived from these factors that accumulate over the lifes-
pan, thus covering most of their predictive value. More-
over, when an established risk factor is considered as a risk
predictor, there is need for sufficient variation within the
population in such risk factor in order to successfully dis-
criminate between high and low risk groups [37]. For
instance, pesticide exposure is associated with incident
dementia [38], but in the general population only few
individuals have been exposed to these substances.
Therefore, at population level the inclusion of such a pre-
dictor has a very limited yield.
Our results furthermore indicate that the predictive
accuracy of all models is poor in participants aged 80 years
or older. This may be explained by the fact that although
the absolute incidence of dementia increases steeply with
increasing age, the relative increase in dementia incidence
is higher in younger (aged 55–79 years) than in older
participants (aged 80 years or older) [20, 39]. A higher
predictive value of an increase in age in the younger
compared to the older group of participants was therefore
not unexpected. Conversely, the incorporated midlife car-
diovascular risk factors in these models will contribute
more to dementia risk for younger participants at elderly
ages. These results emphasize the need for more advanced
modelling of age-specific effects (e.g. non-linear or inter-
action terms) and warrant further development of age-
stratified models. This approach is probably a more likely
key to success in dementia risk prediction modelling, as
age is the main driver of dementia risk. In addition to more
adequate modelling of the effects of age and its interactions
with risk factors, future models could take other useful risk
predictors for dementia into account. These are probably
early minor symptoms of disease, such as subjective
memory complaints. For more augmented models, markers
of subclinical neurodegeneration could be considered, such
as hippocampal atrophy, to improve model performance in
a more specific, clinical setting [40].
Altogether, this study shows that using age alone has
similar predictive accuracy for the occurrence of dementia
compared to risk models incorporating demographic,
health, and lifestyle risk factors. These findings highlight
the limited added value of other predictors currently
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included in these models in dementia prediction above and
beyond age in an elderly population. Additionally, we
mention several methodological considerations that
deserve further attention when developing dementia pre-
diction models. First, it is informative to assess and report
the performance of the full model compared to a model
based on age alone prior to and in addition to external
validation. Second, given distinct differences in risk factor
distributions between men and women, it may be of
additional value to explore the additional value of sex-
specific models. Third, while model discrimination was
appropriately addressed in most of these models, equations
to calculate absolute risks were often not provided—lim-
iting required limiting opportunities for proper validation,
and eventually hampering clinical translation. Finally,
dementia models included in this validation study did not
account for the competing risk of death from other causes,
subsequently inflating apparent dementia risk predictions.
The risk of these competing events is substantial, given the
late-life onset of dementia in the general population and
future models should therefore take this into account [41].
Strengths of this study include the large sample size and
number of events, detailed assessment of dementia and the
wide range of systematically collected covariates, making
this comparison possible. Several general methodological
considerations need to be taken into account for proper
interpretation of our findings. First, although we tried to
compute the risk scores of the models exactly as they were
reported, we had to make several adjustments. These
include some minor adjustments that were made to variable
definitions. Nevertheless, these deviations most likely
represent a good approximation of performance based on
other data that, similarly, will likely not map directly onto
the original variables. Second, there was no data or sur-
rogate marker available in this study on pesticide exposure
and cognitive activity, two predictive variables in the
ANU-ADRI risk score. This may have underestimated the
performance of this score in the Rotterdam Study. Third,
selective attrition cannot be ruled out, yet we believe that
given the high response figures of each study wave (83.0
and 89.1%) along with a virtually-complete follow-up
(97.5%), it is very unlikely that this may have influenced
our results. Finally, as our study population consists of
elderly participants of predominantly Caucasian descent
(97.7%), we cannot generalize our findings individuals up
to 55 years of age or to other ethnicities.
Conclusions
In conclusion, this validation study shows that the perfor-
mance of four models for predicting dementia in an elderly
community-dwelling population using age alone was
nearly identical compared to the full prediction models.
Discriminative abilities of the models varied largely and
was very age-dependent. Transportability of the predicted
risks was generally poor. These findings highlight the
importance of age in the assessment of dementia risk and
indicate a need for improvement and refinement in risk
factor measurement and model development to inform
prediction above and beyond the risk from age alone.
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